Heights Capital Management logo

Heights Capital Management

North America, California, United States, San Francisco

Description

Heights Capital Management, Inc. operates as a specialized affiliate of Susquehanna International Group (SIG), a global quantitative trading firm. Based in San Francisco, Heights Capital focuses primarily on Private Investments in Public Equity (PIPE) transactions, targeting emerging growth companies. Unlike traditional venture capital firms that invest in private startups, Heights Capital provides crucial capital to companies that are already publicly traded or are in the process of going public, often through Special Purpose Acquisition Companies (SPACs). Their investment approach is rooted in providing flexible, non-control growth capital to support various corporate initiatives, including working capital, strategic acquisitions, and product development, for businesses poised for significant expansion in the public markets.

The firm's investment strategy centers on identifying public companies with strong growth potential that require substantial capital infusions. Heights Capital Management is known for its ability to execute complex PIPE deals, offering structured financing solutions that can include convertible notes, preferred stock, or common equity. This flexibility allows them to tailor investments to the specific needs of the issuing company while aligning with their own risk-reward parameters. Their deep expertise in public markets, backed by SIG's extensive financial resources and trading capabilities, enables them to conduct thorough due diligence and provide strategic value beyond just capital.

Heights Capital Management typically deploys significant capital into its target companies. While specific deal sizes can vary widely depending on the company's needs and market conditions, their typical first check sizes for PIPE investments generally range from approximately $10 million to $150 million. For instance, they participated in a $100 million PIPE for Cibus in 2023, and a $150 million PIPE for Ginkgo Bioworks in 2021, demonstrating their capacity for substantial commitments. These large-scale investments underscore their role as a critical funding source for public companies seeking to accelerate their growth trajectories without necessarily resorting to traditional follow-on public offerings, which can be dilutive or subject to volatile market conditions.

Investor Profile

Heights Capital Management has backed more than 24 startups, with 2 new investments in the last 12 months alone. The firm has led 4 rounds, about 17% of its total and boasts 14 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series Unknown, Post Ipo Debt rounds (top funding stages).
  • Majority of deals are located in United States, France, United Kingdom.
  • Strong thematic focus on Biotechnology, Health Care, Medical.
  • Typical check size: $10M – $150M.

Stage Focus

  • Post Ipo Equity (38%)
  • Series Unknown (33%)
  • Post Ipo Debt (17%)
  • Series F (4%)
  • Series C (4%)
  • Series B (4%)

Country Focus

  • United States (54%)
  • France (25%)
  • United Kingdom (8%)
  • Canada (4%)
  • China (4%)
  • Japan (4%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
  • Genetics
  • Manufacturing
  • Oncology
  • Biopharma
  • Mobile
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Heights Capital Management frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 3
DC
North America, Illinois, United States, Deerfield
Co-Investments: 2
Iroquois Capital
North America, Tennessee, United States, Nashville
Co-Investments: 5
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
Dafna Capital Management
North America, California, United States, Los Angeles
Co-Investments: 2
Columbia Capital
North America, Virginia, United States, Alexandria
Co-Investments: 2
FM
North America, California, United States, San Francisco
Co-Investments: 2
ArmaVir Partners
North America, New York, United States, New York
Co-Investments: 2
Highland Capital Partners
North America, Massachusetts, United States, Lexington
Co-Investments: 2
Armistice Capital
North America, New York, United States, New York
Co-Investments: 2

What are some of recent deals done by Heights Capital Management?

SynAct Pharma

Lund, Skane Lan, Sweden

SynAct Pharma develops drugs for acute deterioration in inflammatory diseases.

BiotechnologyHealth Care
Post Ipo EquityJul 15, 2025
Amount Raised: $1,842,301
SEALSQ

Cointrin, Geneve, Switzerland

SEALSQ is a provider of semiconductors that develops secure chips, embedded firmware, and trusted technology hardware and software products.

Embedded SoftwareHardwareSemiconductor
Post Ipo EquityJul 14, 2025
Amount Raised: $60,000,000
IonQ

College Park, Maryland, United States

IONQ offers enterprise-grade quantum systems designed for businesses seeking to harness the power of quantum computing in their operations.

ComputerElectronicsInformation ServicesInformation TechnologyQuantum Computing
Post Ipo EquityJul 7, 2025
Amount Raised: $1,000,000,000
Crossject

Dijon, Bourgogne, France

Crossject specializes in manufacturing and marketing needleless drug self-injection.

Manufacturing
Post Ipo EquityJun 24, 2025
Amount Raised: $6,626,004
Lomond Therapeutics

San Diego, California, United States

Lomond Therapeutics creates pharmacological platforms that target escape mutations.

BiopharmaBiotechnologyHealth CareMedical
Series UnknownNov 4, 2024
Amount Raised: $44,000,000
Claranova

La Garenne-colombes, Ile-de-France, France

Claranova is a developer and publisher of consumer software and business solutions.

Business DevelopmentEnterprise SoftwareInternetMobilePublishingSoftware
Post Ipo DebtApr 2, 2024
Amount Raised: $116,296,349
Crossject

Dijon, Bourgogne, France

Crossject specializes in manufacturing and marketing needleless drug self-injection.

Manufacturing
Post Ipo DebtFeb 27, 2024
Amount Raised: $7,588,347
GenSight Biologics

Paris, Ile-de-France, France

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.

BiotechnologyGeneticsHealth CareMedical
Post Ipo EquityFeb 8, 2024
Amount Raised: $5,388,825
Abivax

Paris, Ile-de-France, France

Abivax develops medicines that alter the body's natural immune system mechanisms.

BiotechnologyHealth CareTherapeutics
Post Ipo DebtAug 21, 2023
Amount Raised: $163,465,824
GenSight Biologics

Paris, Ile-de-France, France

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.

BiotechnologyGeneticsHealth CareMedical
Post Ipo DebtDec 23, 2022
Amount Raised: $12,800,423